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Narrative Abstract
Re-institution of reflex testing of stool submitted for Clostridium difficile testing for vancomycin-
resistant enterococci (VRE) reduced the incidence of healthcare-associated VRE bacteremia and 
bacteriuria compared to when testing was not in place (1.9 versus 3.3 cases per 10,000 patient 
days when testing was not in use).
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Introduction
Vancomycin-resistant enterococci (VRE) infections result in increased hospital costs and 
length of stay (1). Previously, we described a hospital-wide “reflex” testing program for 
detecting VRE intestinal colonization as an intervention to limit nosocomial transmission. 
Inpatients that had diarrheal stools submitted to the clinical microbiology laboratory for 
Clostridium difficile (C. difficile) toxin testing also had screening cultures for VRE (2). In 
July 2010, this program was discontinued and in the subsequent 18 months, the monthly 
incidence of healthcare-associated VRE increased by 71%.
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Based on these findings the VRE reflex testing program was re-instituted in January 2012. 
We examined the effect of re-institution of the VRE reflex testing program on healthcare-
associated VRE incidence.
Methods
Barnes-Jewish Hospital is a 1,250-bed academic tertiary care hospital in Saint Louis, 
Missouri. We examined the healthcare-associated VRE rate between January 2009 and 
December 2015. Reflex testing for VRE was discontinued in July 2010 and re-instituted in 
January 2012. Clinicians were notified of these changes to VRE reflex testing. Throughout 
the study period, clinicians could order stool or peri-rectal cultures for VRE testing at their 
discretion. Hospital policy during the study was to place VRE colonized or infected patients 
in contact precautions in a private room. During the reflex screening period 1 (January 2009 
to July 2010), stool specimens were plated out on BD Enterococcosel Agar (Becton 
Dickinson, Sparks, Maryland). In the screening period 2 (January 2012 to December 2015), 
chromID VRE (bioMerieux, Durham, NC) was used. There was no difference in the 
screening cultures performed that were positive for VRE in either screening periods [25.5% 
(2457/9637) in period 1 versus 25.2% (6289/24920) in period 2; p = 0.62].
All hospitalized patients with a positive urine or blood culture for VRE were identified. A 
healthcare-associated VRE case was defined as the first positive specimen per patient, where 
VRE was detected in blood or urine ≥ 3 calendar days after admission. A VRE case was 
considered present on admission if VRE was detected in blood or urine < 3 calendar days 
after admission (3). In the original study, we defined healthcare-associated VRE as initial 
culture within 48 hours after admission. The VRE incidence was expressed as cases per 
10,000 patient-days.
The effect of reflex testing on the incidence of healthcare-associated VRE was evaluated 
using regression models with autoregressive integrated moving average (ARIMA) errors. In 
addition to reflex testing, VRE prevalence on admission, central line utilization, urinary 
catheter utilization, and overall temporal trend were considered in the model to evaluate the 
effects of these factors on healthcare-associated VRE rate during the study period. The 
Washington University Human Research Protection Office approved this study.
Results
There were 99 cases [blood =36 (36.3%), urine =63 (66.6%)] of healthcare-associated VRE 
(2.3/10,000 patient-days) in the initial reflex testing period, 166 cases [blood=63 (38.0%), 
urine=103 (62.0%)] when reflex testing was discontinued (3.7/10,000 patient-days), and 218 
cases [blood=57 (26.1%), urine=161 (73.9%)] after reflex testing was re-instituted 
(1.8/10,000 patient-days) (Figure). Accounting for the overall temporal trend, healthcare-
associated VRE decreased at a rate of 36.4% (−36.4, 95% CI: −50.9, −17.7) per month 
during the entire study period. The average healthcare-associated VRE rate was 1.9/10,000 
patient-days during the reflex testing periods, versus 3.7/10,000 patient-days during the non-
testing period. When adjusted for VRE prevalence on admission and overall temporal trend, 
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reflex testing was associated with 32.0% (−32.0; 95% CI: −48.2, −10.8) reduction in 
healthcare-associated VRE incidence compared to the non-reflex testing period.
Conclusion
In this follow-up study, we noted that hospital-wide re-institution of a VRE reflex screening 
program led to a decrease in hospital-associated VRE incidence to a baseline rate similar to 
pre-discontinuation period, which further suggested a causal relationship between the 
program and a reduction in hospital-associated VRE transmission (4). Most hospitals, often 
due to the lack of routine active surveillance, do not identify a large proportion of colonized 
patients who are potential sources for ongoing hospital transmission (5, 6). Some studies 
have demonstrated the benefit of active surveillance cultures to control VRE transmission in 
hospitals; however, these were generally done during an outbreak in which multiple 
interventions were introduced simultaneously (7, 8). In our previous study, we found that 
discontinuation of reflex VRE testing of stool submitted for testing for C. difficile at our 
hospital resulted in a 71% increase in the endemic healthcare-associated VRE rate (Figure). 
This long-term, follow-up analysis suggested that when reflex VRE testing was re-
implemented, healthcare-associated VRE rates returned to our pre-discontinuation baseline.
Limitations of our study included data from a single care center and lack of information on 
patient-level characteristics. Other concern may be due to change in the screening method of 
stool specimens. However, the percent of positive screening tests did not change 
significantly. Strengths of the study include repeated treatment design (9) and use of 
regression models with ARIMA errors to appropriately account for correlated observations 
over time and to adjust for the overall temporal trend and important confounders such as 
VRE prevalence on admission. Furthermore, no other specific infection prevention measures 
were implemented over the study timeframe, and laboratory methods for identifying VRE 
from urine and blood cultures did not change. Also there were no outbreaks of C. difficile 
during this period.
In conclusion, we found that the use of VRE reflex testing of stool submitted to C. difficile 
testing was effective in reducing the incidence of hospital-associated VRE infections when 
combined with contact precautions program. This should be considered as a valid strategy to 
reduce VRE transmission in hospital settings.
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Monthly incidence of healthcare-associated vancomycin resistant enterococci (VRE) 
infections, January 2009 – December 2015
*Rate adjusting for overall temporal trend and VRE prevalence on admission by 
Autoregressive integrated moving average.
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